Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Diversity Considerations in HIV-1 Vaccine Selection
Brian Gaschen,1Jesse Taylor,1Karina Yusim,1Brian Foley,1Feng Gao,2Dorothy Lang,1Vladimir Novitsky,3Barton Haynes,2Beatrice H. Hahn,4Tanmoy Bhattacharya,1Bette Korber15*
Globally, human immunodeficiency virus-type 1 (HIV-1) is extraordinarily variable, and this diversity poses a major
obstacleto AIDS vaccine development. Currently, candidate vaccines arederived from isolates, with the hope that they will be sufficientlycross-reactive to protect against circulating viruses. This maybe
overly optimistic, however, given that HIV-1 envelope proteinscan
differ in more than 30% of their amino acids. To contend withthe
diversity, country-specific vaccines are being considered,but
evolutionary relationships may be more useful than regionalconsiderations. Consensus or ancestor sequences could be usedin
vaccine design to minimize the genetic differences betweenvaccine
strains and contemporary isolates, effectively reducingthe extent of
diversity by half.
1 Los Alamos National Laboratory, Los Alamos,
NM 87545, USA.
2 Duke University AIDS Center,
Durham, NC 27710, USA.
3 Department of Immunology
and Infectious Diseases, Harvard School of Public Health, Boston, MA
02115, USA.
4 University of Alabama at Birmingham,
Birmingham, AL 35294, USA.
5 Santa Fe Institute,
Santa Fe, NM 87501, USA.
*
To whom correspondence should be addressed. E-mail:
btk{at}t10.lanl.gov
The editors suggest the following Related Resources on Science sites:
In Science Magazine
LETTERS
David C. Nickle, Mark A. Jensen, Geoffrey S. Gottlieb, Daniel Shriner, Gerald H. Learn, Allen G. Rodrigo, James I. Mullins;, F. Gao, T. Bhattacharya, B. Gaschen, J. Taylor, J. P. Moore, V. Novitsky, K. Yusim, D. Lang, B. Foley, S. Beddows, M. Alam, B. Haynes, B. H. Hahn, and B. Korber (7 March 2003) Science299 (5612), 1515c.
[DOI: 10.1126/science.299.5612.1515c] |Full Text »|PDF »
NEWS FOCUS
Jon Cohen (28 June 2002) Science296 (5577), 2320.
[DOI: 10.1126/science.296.5577.2320] |Summary »|Full Text »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Web-based design and evaluation of T-cell vaccine candidates.
J. Thurmond, H. Yoon, C. Kuiken, K. Yusim, S. Perkins, J. Theiler, T. Bhattacharya, B. Korber, and W. Fischer (2008)
Bioinformatics
24, 1639-1640
|Abstract »|PDF »
Tissue Transglutaminase Activation Modulates Inflammation in Cystic Fibrosis via PPAR{gamma} Down-Regulation.
L. Maiuri, A. Luciani, I. Giardino, V. Raia, V. R. Villella, M. D'Apolito, M. Pettoello-Mantovani, S. Guido, C. Ciacci, M. Cimmino, et al. (2008)
J. Immunol.
180, 7697-7705
|Abstract »|Full Text »|PDF »
Patterns of CD8+ Immunodominance May Influence the Ability of Mamu-B*08-Positive Macaques To Naturally Control Simian Immunodeficiency Virus SIVmac239 Replication.
J. T. Loffredo, A. T. Bean, D. R. Beal, E. J. Leon, G. E. May, S. M. Piaskowski, J. R. Furlott, J. Reed, S. K. Musani, E. G. Rakasz, et al. (2008)
J. Virol.
82, 1723-1738
|Abstract »|Full Text »|PDF »
The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection.
P. L. Moore, E. S. Gray, I. A. Choge, N. Ranchobe, K. Mlisana, S. S. Abdool Karim, C. Williamson, L. Morris, and and the CAPRISA 002 Study Team (2008)
J. Virol.
82, 1860-1869
|Abstract »|Full Text »|PDF »
Induction of Broad Cross-Subtype-Specific HIV-1 Immune Responses by a Novel Multivalent HIV-1 Peptide Vaccine in Cynomolgus Macaques.
A. Azizi, D. E. Anderson, J. V. Torres, A. Ogrel, M. Ghorbani, C. Soare, P. Sandstrom, J. Fournier, and F. Diaz-Mitoma (2008)
J. Immunol.
180, 2174-2186
|Abstract »|Full Text »|PDF »
The hepatitis C sequence database in Los Alamos.
C. Kuiken, P. Hraber, J. Thurmond, and K. Yusim (2008)
Nucleic Acids Res.
36, D512-D516
|Abstract »|Full Text »|PDF »
From the Cover: The emergence of HIV/AIDS in the Americas and beyond.
M. T. P. Gilbert, A. Rambaut, G. Wlasiuk, T. J. Spira, A. E. Pitchenik, and M. Worobey (2007)
PNAS
104, 18566-18570
|Abstract »|Full Text »|PDF »
Increased Sequence Diversity Coverage Improves Detection of HIV-Specific T Cell Responses.
N. Frahm, D. E. Kaufmann, K. Yusim, M. Muldoon, C. Kesmir, C. H. Linde, W. Fischer, T. M. Allen, B. Li, B. H. McMahon, et al. (2007)
J. Immunol.
179, 6638-6650
|Abstract »|Full Text »|PDF »
Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications.
L. Buonaguro, M. L. Tornesello, and F. M. Buonaguro (2007)
J. Virol.
81, 10209-10219
|Full Text »|PDF »
N-Linked Glycan Modifications in gp120 of Human Immunodeficiency Virus Type 1 Subtype C Render Partial Sensitivity to 2G12 Antibody Neutralization.
E. S. Gray, P. L. Moore, R. A. Pantophlet, and L. Morris (2007)
J. Virol.
81, 10769-10776
|Abstract »|Full Text »|PDF »
Envelope variation as a primary determinant of lentiviral vaccine efficacy.
J. K. Craigo, B. Zhang, S. Barnes, T. L. Tagmyer, S. J. Cook, C. J. Issel, and R. C. Montelaro (2007)
PNAS
104, 15105-15110
|Abstract »|Full Text »|PDF »
Reconstruction and Function of Ancestral Center-of-Tree Human Immunodeficiency Virus Type 1 Proteins.
M. Rolland, M. A. Jensen, D. C. Nickle, J. Yan, G. H. Learn, L. Heath, D. Weiner, and J. I. Mullins (2007)
J. Virol.
81, 8507-8514
|Abstract »|Full Text »|PDF »
Unique Mutational Patterns in the Envelope {alpha}2 Amphipathic Helix and Acquisition of Length in gp120 Hypervariable Domains Are Associated with Resistance to Autologous Neutralization of Subtype C Human Immunodeficiency Virus Type 1.
R. Rong, S. Gnanakaran, J. M. Decker, F. Bibollet-Ruche, J. Taylor, J. N. Sfakianos, J. L. Mokili, M. Muldoon, J. Mulenga, S. Allen, et al. (2007)
J. Virol.
81, 5658-5668
|Abstract »|Full Text »|PDF »
Mitochondrial diversity within modern human populations.
Enhanced Detection of Human Immunodeficiency Virus Type 1 (HIV-1) Nef-Specific T Cells Recognizing Multiple Variants in Early HIV-1 Infection.
U. Malhotra, F. Li, J. Nolin, M. Allison, H. Zhao, J. I. Mullins, S. Self, and M. J. McElrath (2007)
J. Virol.
81, 5225-5237
|Abstract »|Full Text »|PDF »
Clade-Specific Differences between Human Immunodeficiency Virus Type 1 Clades B and C: Diversity and Correlations in C3-V4 Regions of gp120.
S. Gnanakaran, D. Lang, M. Daniels, T. Bhattacharya, C. A. Derdeyn, and B. Korber (2007)
J. Virol.
81, 4886-4891
|Abstract »|Full Text »|PDF »
Role of V1V2 and Other Human Immunodeficiency Virus Type 1 Envelope Domains in Resistance to Autologous Neutralization during Clade C Infection.
R. Rong, F. Bibollet-Ruche, J. Mulenga, S. Allen, J. L. Blackwell, and C. A. Derdeyn (2007)
J. Virol.
81, 1350-1359
|Abstract »|Full Text »|PDF »
Modulation of DNA Vaccine-Elicited CD8+ T-Lymphocyte Epitope Immunodominance Hierarchies.
J. Liu, B. A. Ewald, D. M. Lynch, A. Nanda, S. M. Sumida, and D. H. Barouch (2006)
J. Virol.
80, 11991-11997
|Abstract »|Full Text »|PDF »
Significance of Variation Within HIV, EBV, and KSHV Subtypes..
J. Stebbing, T. Powles, M. Nelson, and M. Bower (2006)
J Int Assoc Physicians AIDS Care (Chic Ill)
5, 93-102
|Abstract »|PDF »
Cross-Subtype T-Cell Immune Responses Induced by a Human Immunodeficiency Virus Type 1 Group M Consensus Env Immunogen.
E. A. Weaver, Z. Lu, Z. T. Camacho, F. Moukdar, H.-X. Liao, B.-J. Ma, M. Muldoon, J. Theiler, G. J. Nabel, N. L. Letvin, et al. (2006)
J. Virol.
80, 6745-6756
|Abstract »|Full Text »|PDF »
Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1..
B. Li, J. M. Decker, R. W. Johnson, F. Bibollet-Ruche, X. Wei, J. Mulenga, S. Allen, E. Hunter, B. H. Hahn, G. M. Shaw, et al. (2006)
J. Virol.
80, 5211-5218
|Abstract »|Full Text »|PDF »
Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239..
N. A. Wilson, J. Reed, G. S. Napoe, S. Piaskowski, A. Szymanski, J. Furlott, E. J. Gonzalez, L. J. Yant, N. J. Maness, G. E. May, et al. (2006)
J. Virol.
80, 5875-5885
|Abstract »|Full Text »|PDF »
MOLECULAR EPIDEMIOLOGY OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INDIVIDUALS IN MEDELLIN, COLOMBIA.
G. I. SANCHEZ, C. T. BAUTISTA, L. EYZAGUIRRE, G. CARRION, S. ARIAS, W. B. SATEREN, M. NEGRETE, S. M. MONTANO, J. L. SANCHEZ, and J. K. CARR (2006)
Am J Trop Med Hyg
74, 674-677
|Abstract »|Full Text »|PDF »
Impact of HLA-B Alleles, Epitope Binding Affinity, Functional Avidity, and Viral Coinfection on the Immunodominance of Virus-Specific CTL Responses.
F. Bihl, N. Frahm, L. Di Giammarino, J. Sidney, M. John, K. Yusim, T. Woodberry, K. Sango, H. S. Hewitt, L. Henry, et al. (2006)
J. Immunol.
176, 4094-4101
|Abstract »|Full Text »|PDF »
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus.
R. Draenert, T. M. Allen, Y. Liu, T. Wrin, C. Chappey, C. L. Verrill, G. Sirera, R. L. Eldridge, M. P. Lahaie, L. Ruiz, et al. (2006)
J. Exp. Med.
203, 529-539
|Abstract »|Full Text »|PDF »
Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control.
R. Zuniga, A. Lucchetti, P. Galvan, S. Sanchez, C. Sanchez, A. Hernandez, H. Sanchez, N. Frahm, C. H. Linde, H. S. Hewitt, et al. (2006)
J. Virol.
80, 3122-3125
|Abstract »|Full Text »|PDF »
Human Immunodeficiency Virus Type 1 env Evolves toward Ancestral States upon Transmission to a New Host.
J. T. Herbeck, D. C. Nickle, G. H. Learn, G. S. Gottlieb, M. E. Curlin, L. Heath, and J. I. Mullins (2006)
J. Virol.
80, 1637-1644
|Abstract »|Full Text »|PDF »
Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial.
W. A. Burgers, J. H. van Harmelen, E. Shephard, C. Adams, T. Mgwebi, W. Bourn, T. Hanke, A.-L. Williamson, and C. Williamson (2006)
J. Gen. Virol.
87, 399-410
|Abstract »|Full Text »|PDF »
Effects of Immunization with CCR5-Based Cycloimmunogen on Simian/HIVSF162P3 Challenge.
S. Misumi, D. Nakayama, M. Kusaba, T. Iiboshi, R. Mukai, K. Tachibana, T. Nakasone, M. Umeda, H. Shibata, M. Endo, et al. (2006)
J. Immunol.
176, 463-471
|Abstract »|Full Text »|PDF »
Selective Escape from CD8+ T-Cell Responses Represents a Major Driving Force of Human Immunodeficiency Virus Type 1 (HIV-1) Sequence Diversity and Reveals Constraints on HIV-1 Evolution.
T. M. Allen, M. Altfeld, S. C. Geer, E. T. Kalife, C. Moore, K. M. O'Sullivan, I. DeSouza, M. E. Feeney, R. L. Eldridge, E. L. Maier, et al. (2005)
J. Virol.
79, 13239-13249
|Abstract »|Full Text »|PDF »
Evaluation of Envelope Vaccines Derived from the South African Subtype C Human Immunodeficiency Virus Type 1 TV1 Strain.
Y. Lian, I. Srivastava, V. R. Gomez-Roman, J. zur Megede, Y. Sun, E. Kan, S. Hilt, S. Engelbrecht, S. Himathongkham, P. A. Luciw, et al. (2005)
J. Virol.
79, 13338-13349
|Abstract »|Full Text »|PDF »
Extensive Antigenic Polymorphism within the Repeat Sequence of the Plasmodium falciparum Merozoite Surface Protein 1 Block 2 Is Incorporated in a Minimal Polyvalent Immunogen.
K. K. A. Tetteh, D. R. Cavanagh, P. Corran, R. Musonda, J. S. McBride, and D. J. Conway (2005)
Infect. Immun.
73, 5928-5935
|Abstract »|Full Text »|PDF »
Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope.
N. A. Doria-Rose, G. H. Learn, A. G. Rodrigo, D. C. Nickle, F. Li, M. Mahalanabis, M. T. Hensel, S. McLaughlin, P. F. Edmonson, D. Montefiori, et al. (2005)
J. Virol.
79, 11214-11224
|Abstract »|Full Text »|PDF »
Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies.
M. Li, F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, et al. (2005)
J. Virol.
79, 10108-10125
|Abstract »|Full Text »|PDF »
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus.
S. C. Ray, L. Fanning, X.-H. Wang, D. M. Netski, E. Kenny-Walsh, and D. L. Thomas (2005)
J. Exp. Med.
201, 1753-1759
|Abstract »|Full Text »|PDF »
The Majority of Currently Circulating Human Immunodeficiency Virus Type 1 Clade B Viruses Fail To Prime Cytotoxic T-Lymphocyte Responses against an Otherwise Immunodominant HLA-A2-Restricted Epitope: Implications for Vaccine Design.
M. Altfeld, T. M. Allen, E. T. Kalife, N. Frahm, M. M. Addo, B. R. Mothe, A. Rathod, L. L. Reyor, J. Harlow, X. G. Yu, et al. (2005)
J. Virol.
79, 5000-5005
|Abstract »|Full Text »|PDF »
Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys.
M. S. Seaman, L. Xu, K. Beaudry, K. L. Martin, M. H. Beddall, A. Miura, A. Sambor, B. K. Chakrabarti, Y. Huang, R. Bailer, et al. (2005)
J. Virol.
79, 2956-2963
|Abstract »|Full Text »|PDF »
The Los Alamos hepatitis C sequence database.
C. Kuiken, K. Yusim, L. Boykin, and R. Richardson (2005)
Bioinformatics
21, 379-384
|Abstract »|Full Text »|PDF »
Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein.
F. Gao, E. A. Weaver, Z. Lu, Y. Li, H.-X. Liao, B. Ma, S. M. Alam, R. M. Scearce, L. L. Sutherland, J.-S. Yu, et al. (2005)
J. Virol.
79, 1154-1163
|Abstract »|Full Text »|PDF »
Mutations in the RNase H Primer Grip Domain of Murine Leukemia Virus Reverse Transcriptase Decrease Efficiency and Accuracy of Plus-Strand DNA Transfer.
J. L. Mbisa, G. N. Nikolenko, and V. K. Pathak (2005)
J. Virol.
79, 419-427
|Abstract »|Full Text »|PDF »
A Dominant Role for CD8+-T-Lymphocyte Selection in Simian Immunodeficiency Virus Sequence Variation.
D. H. O'Connor, A. B. McDermott, K. C. Krebs, E. J. Dodds, J. E. Miller, E. J. Gonzalez, T. J. Jacoby, L. Yant, H. Piontkivska, R. Pantophlet, et al. (2004)
J. Virol.
78, 14012-14022
|Abstract »|Full Text »|PDF »
Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies.
J. M. Binley, T. Wrin, B. Korber, M. B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, et al. (2004)
J. Virol.
78, 13232-13252
|Abstract »|Full Text »|PDF »
Antigenic Diversity and Immune Evasion by Malaria Parasites.
M. U. Ferreira, M. da Silva Nunes, and G. Wunderlich (2004)
Clin. Vaccine Immunol.
11, 987-995
|Full Text »|PDF »
Recognition of Variant HIV-1 Epitopes from Diverse Viral Subtypes by Vaccine-Induced CTL.
D. M. McKinney, R. Skvoretz, B. D. Livingston, C. C. Wilson, M. Anders, R. W. Chesnut, A. Sette, M. Essex, V. Novitsky, and M. J. Newman (2004)
J. Immunol.
173, 1941-1950
|Abstract »|Full Text »|PDF »
Sequencing-Based Detection of Low-Frequency Human Immunodeficiency Virus Type 1 Drug-Resistant Mutants by an RNA/DNA Heteroduplex Generator-Tracking Assay.
A. Kapoor, M. Jones, R. W. Shafer, S.-Y. Rhee, P. Kazanjian, and E. L. Delwart (2004)
J. Virol.
78, 7112-7123
|Abstract »|Full Text »|PDF »
Mapping Sites of Positive Selection and Amino Acid Diversification in the HIV Genome: An Alternative Approach to Vaccine Design?.
T. de Oliveira, M. Salemi, M. Gordon, A.-M. Vandamme, E. J. van Rensburg, S. Engelbrecht, H. M. Coovadia, and S. Cassol (2004)
Genetics
167, 1047-1058
|Abstract »|Full Text »|PDF »
Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins.
H.-X. Liao, S. M. Alam, J. R. Mascola, J. Robinson, B. Ma, D. C. Montefiori, M. Rhein, L. L. Sutherland, R. Scearce, and B. F. Haynes (2004)
J. Virol.
78, 5270-5278
|Abstract »|Full Text »|PDF »
Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease Inhibitors.
C. Charpentier, D. E. Dwyer, F. Mammano, D. Lecossier, F. Clavel, and A. J. Hance (2004)
J. Virol.
78, 4234-4247
|Abstract »|Full Text »|PDF »
DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade.
M. Giri, K. E. Ugen, and D. B. Weiner (2004)
Clin. Microbiol. Rev.
17, 370-389
|Abstract »|Full Text »|PDF »
SYBR Green-Based Real-Time Quantitative PCR Assay for Detection of West Nile Virus Circumvents False-Negative Results Due to Strain Variability.
J. F. Papin, W. Vahrson, and D. P. Dittmer (2004)
J. Clin. Microbiol.
42, 1511-1518
|Abstract »|Full Text »|PDF »
Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission.
C. A. Derdeyn, J. M. Decker, F. Bibollet-Ruche, J. L. Mokili, M. Muldoon, S. A. Denham, M. L. Heil, F. Kasolo, R. Musonda, B. H. Hahn, et al. (2004)
Science
303, 2019-2022
|Abstract »|Full Text »|PDF »
Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities.
N. Frahm, B. T. Korber, C. M. Adams, J. J. Szinger, R. Draenert, M. M. Addo, M. E. Feeney, K. Yusim, K. Sango, N. V. Brown, et al. (2004)
J. Virol.
78, 2187-2200
|Abstract »|Full Text »|PDF »
Antibody-targeted MHC complex-directed expansion of HIV-1- and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccination.
J. Stebbing, B. Gazzard, S. Patterson, M. Bower, D. Perumal, M. Nelson, A. McMichael, G. Ogg, A. Epenetos, F. Gotch, et al. (2004)
Blood
103, 1791-1795
|Abstract »|Full Text »|PDF »
Comparative Study of Adaptive Molecular Evolution in Different Human Immunodeficiency Virus Groups and Subtypes.
M. Choisy, C. H. Woelk, J.-F. Guegan, and D. L. Robertson (2004)
J. Virol.
78, 1962-1970
|Abstract »|Full Text »|PDF »
Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice.
A. Jaffray, E. Shephard, J. van Harmelen, C. Williamson, A.-L. Williamson, and E. P. Rybicki (2004)
J. Gen. Virol.
85, 409-413
|Abstract »|Full Text »|PDF »
Impaired Processing and Presentation of Cytotoxic-T-Lymphocyte (CTL) Epitopes Are Major Escape Mechanisms from CTL Immune Pressure in Human Immunodeficiency Virus Type 1 Infection.
Y. Yokomaku, H. Miura, H. Tomiyama, A. Kawana-Tachikawa, M. Takiguchi, A. Kojima, Y. Nagai, A. Iwamoto, Z. Matsuda, and K. Ariyoshi (2004)
J. Virol.
78, 1324-1332
|Abstract »|Full Text »|PDF »
Human Immunodeficiency Virus Type 1 Superinfection Was Not Detected following 215 Years of Injection Drug User Exposure.
R. Tsui, B. L. Herring, J. D. Barbour, R. M. Grant, P. Bacchetti, A. Kral, B. R. Edlin, and E. L. Delwart (2004)
J. Virol.
78, 94-103
|Abstract »|Full Text »|PDF »
Development of a DNA Vaccine Designed to Induce Cytotoxic T Lymphocyte Responses to Multiple Conserved Epitopes in HIV-1.
C. C. Wilson, D. McKinney, M. Anders, S. MaWhinney, J. Forster, C. Crimi, S. Southwood, A. Sette, R. Chesnut, M. J. Newman, et al. (2003)
J. Immunol.
171, 5611-5623
|Abstract »|Full Text »|PDF »
The entry of entry inhibitors: A fusion of science and medicine.
Enhanced Detection of Human Immunodeficiency Virus Type 1-Specific T-Cell Responses to Highly Variable Regions by Using Peptides Based on Autologous Virus Sequences.
M. Altfeld, M. M. Addo, R. Shankarappa, P. K. Lee, T. M. Allen, X. G. Yu, A. Rathod, J. Harlow, K. O'Sullivan, M. N. Johnston, et al. (2003)
J. Virol.
77, 7330-7340
|Abstract »|Full Text »|PDF »
Molecular Characteristics of Human Immunodeficiency Virus Type 1 Subtype C Viruses from KwaZulu-Natal, South Africa: Implications for Vaccine and Antiretroviral Control Strategies.
M. Gordon, T. De Oliveira, K. Bishop, H. M. Coovadia, L. Madurai, S. Engelbrecht, E. Janse van Rensburg, A. Mosam, A. Smith, and S. Cassol (2003)
J. Virol.
77, 2587-2599
|Abstract »|Full Text »|PDF »
